ScreenerHero

VTRS Viatris Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · viatris.com
17.62USD+0.11%Mkt Cap: 20.24B $P/E: —

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation
$23.01BUSDP/E 19.2
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc.
$14.66BUSDP/E 21.1
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc
$7.17BUSDP/E 112.5
AMRX
Amneal Pharmaceuticals, Inc.
$7.09BUSDP/E 41.5
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc.
$6.54BUSDP/E 24.3
KNSA
Kiniksa Pharmaceuticals International, plc
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.
$5.17BUSD
INDV
Indivior Pharmaceuticals, Inc.
$4.25BUSDP/E 12.9

Key Statistics

Company
Market Cap20.24B USD
Enterprise Value32.33B USD
Revenue (TTM)14.74B USD
Gross Profit5.01B USD
Net Income (TTM)-3.51B USD
Revenue/Share12.71 USD
Last Price17.62 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees30.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)6.58
PEG3.20
EV/EBITDA7.53
EV/Revenue2.19
P/S1.37
P/B1.40
EPS (TTM)-0.36
EPS (Forward)2.67
52W Range
9.43091% of range18.43
52W High18.43 USD
52W Low9.430 USD
Profitability
Gross Margin35.06%
Oper. Margin12.55%
EBITDA Margin29.13%
Profit Margin-24.58%
ROE-23.89%
ROA-9.45%
Growth
Revenue Growth4.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF2.32B USD
CapEx (TTM)465.10M USD
FCF Margin18.17%
FCF Yield13.23%
Net Debt12.11B USD
Net Debt/EBITDA2.82
Balance Sheet
Debt/Equity1.00
Current Ratio1.58
Quick Ratio0.82
Book Value/Sh12.59 USD
Cash/Share1.31 USD
Dividends
Fwd Div Rate0.48 USD
Trail. Div Rate0.48 USD
Div. Yield2.73%
5Y Avg Yield3.87%
Payout Ratio960.00%
Ex-Div DateAug 21, 2026
Pay DateSep 16, 2026
Splits
Last Split3:2
Split DateOct 9, 2003
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)19.40 USD
Upside (mean)+10.1%
Target Range13.00 USD – 25.00 USD
13.00+10.1% to mean25.00
# Analysts10
Ownership
Shares Out.1.15B
Float1.14B
Insiders0.32%
Institutions93.48%
Short Interest
Short Ratio5.5d
Short % Float3.56%
Short % Out.3.55%
Shares Short40.79M
Short (prev mo.)37.02M
Technical
SMA 5016.94 (+4.0%)
SMA 20015.32 (+15.0%)
Beta0.88
S&P 52W Chg14.58%
Avg Vol (30d)8.25M
Avg Vol (10d)9.75M
Technical Indicators
RSI (14)57.4
MACD0.2766
MACD Signal0.2291
MACD Hist.+0.0475
BB Upper18.29 USD
BB Middle17.19 USD
BB Lower16.10 USD
BB Width12.71%
ATR (14)0.4664 USD
Vol Ratio (20d)0.72x